These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34863942)

  • 1. The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
    Colca JR; Scherer PE
    Mol Metab; 2022 Jan; 55():101409. PubMed ID: 34863942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
    Vigueira PA; McCommis KS; Hodges WT; Schweitzer GG; Cole SL; Oonthonpan L; Taylor EB; McDonald WG; Kletzien RF; Colca JR; Finck BN
    Exp Physiol; 2017 Aug; 102(8):985-999. PubMed ID: 28597936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease.
    Shannon CE; Ragavan M; Palavicini JP; Fourcaudot M; Bakewell TM; Valdez IA; Ayala I; Jin ES; Madesh M; Han X; Merritt ME; Norton L
    Mol Metab; 2021 Mar; 45():101154. PubMed ID: 33359401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root.
    Colca J
    Expert Opin Investig Drugs; 2020 Feb; 29(2):191-196. PubMed ID: 31928475
    [No Abstract]   [Full Text] [Related]  

  • 5. Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases.
    Colca JR; Tanis SP; McDonald WG; Kletzien RF
    Expert Opin Investig Drugs; 2014 Jan; 23(1):1-7. PubMed ID: 24073940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial target of thiazolidinediones.
    Colca JR; McDonald WG; Kletzien RF
    Diabetes Obes Metab; 2014 Nov; 16(11):1048-54. PubMed ID: 24774061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
    Henry RR
    Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent findings concerning thiazolidinediones in the treatment of diabetes.
    Boden G; Zhang M
    Expert Opin Investig Drugs; 2006 Mar; 15(3):243-50. PubMed ID: 16503761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance and its treatment by thiazolidinediones.
    Lebovitz HE; Banerji MA
    Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
    van der Meer RW; Rijzewijk LJ; de Jong HW; Lamb HJ; Lubberink M; Romijn JA; Bax JJ; de Roos A; Kamp O; Paulus WJ; Heine RJ; Lammertsma AA; Smit JW; Diamant M
    Circulation; 2009 Apr; 119(15):2069-77. PubMed ID: 19349323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
    Fruci B; Giuliano S; Mazza A; Malaguarnera R; Belfiore A
    Int J Mol Sci; 2013 Nov; 14(11):22933-66. PubMed ID: 24264040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis.
    Murdolo G; Smith U
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16 Suppl 1():S35-8. PubMed ID: 16530128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment.
    Cariou B
    Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():15-27. PubMed ID: 35014161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease.
    Gaggini M; Morelli M; Buzzigoli E; DeFronzo RA; Bugianesi E; Gastaldelli A
    Nutrients; 2013 May; 5(5):1544-60. PubMed ID: 23666091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaspin: a novel serpin with insulin-sensitizing effects.
    Wada J
    Expert Opin Investig Drugs; 2008 Mar; 17(3):327-33. PubMed ID: 18321232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
    Seufert J; Lübben G; Dietrich K; Bates PC
    Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA miR-222 mediates pioglitazone beneficial effects on skeletal muscle of diet-induced obese mice.
    de Mendonça M; de Sousa É; da Paixão AO; Araújo Dos Santos B; Roveratti Spagnol A; Murata GM; Araújo HN; Imamura de Lima T; Passos Simões Fróes Guimarães DS; Silveira LR; Rodrigues AC
    Mol Cell Endocrinol; 2020 Feb; 501():110661. PubMed ID: 31770568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.